Genetic Based Analysis in Hypertensive Patients

Hypertension Clinical Trial

Official title:

Genetic Based Analysis of Identifying Predictors of Blood Pressure Response in Hypertensive Patients After Renal Denervation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04321044
• Other study ID #: CRC2019GBA
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 1, 2019
• Est. completion date: December 31, 2023

Study information

• Verified date: July 2023
• Source: University of Erlangen-Nürnberg Medical School
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Many attempts to identify predictors of blood pressure response after renal denervation failed to identify a meaningful determination of blood pressure response.

These attempts have been based on demographic parameters, clinical parameters, endocrine inflammatory and other biochemical variables, comorbidities and disease factors. So far the only predictor of blood pressure response is the pre-treatment blood pressure. According to Wilder's law the pre-treatment baseline value is always a determinant for any change due to an intervention, irrespective which biological variable is examined.

The investigators propose a genetic approach to identify predictors of blood pressure response after renal denervation. Genetic factors are not subject to changes of clinical parameters, previous or current antihypertensive therapy, hypertension associated organ damages, comorbidities and other potential clinical variables.

Description:

Background:

Up to now numerous attempts to identify predictors of blood pressure response after renal denervation failed to identify a meaningful and consistent determinant of blood pressure response. These approaches have been based on demographic parameters, clinical parameters, comorbidities and disease factors as well as numerous endocrine inflammatory and other biochemical variables. Only the pre-treatment blood pressure emerged as a predictor of blood pressure response which is no surprise since according to Wilder's law the pre-treatment baseline value is always a determinant for any change due to an intervention, irrespective which biological variable is examined, e.g. blood pressure, LDL cholesterol, HbA1c and so on.

The investigators suggest a genetic approach to identify predictors of blood pressure response after renal denervation. The rationale is quite simple: Genetic factors are not subject to changes of clinical parameters, previous or current antihypertensive therapy, hypertension associated organ damages, comorbidities, and other potential clinical variables. By such an approach the investigators previously were very successful to identify several parameters of modulators hypertensive organ damage that could not have been identified by pathophysiological or pharmaceutical maneuvers. THE INVESTIGATORS PREFER TO RUN A GENOM WIDE ASSOCIATION STUDY AND THE PARTNERS IN GLASGOW AND EDINBURGH HAVE THE DEEP KNOWLWEDGE; EXPERIENCE AND CAPACITY TO RUN A NGS (next generation sequencing, so that's the complete genome)) INCLUDING ALL BIOINFORMATICS AND OTHER ANALYSIS

Objective:

The investigators attempt to identify predictors of blood pressure response to renal denervation by using a GWAS (genome wide association study) approach. This allows to identify various suspected and unexpected polymorphism that are of interest and potentially being strong predictors of blood pressure response. By that approach the investigators will identify novel mechanism of action that are important for blood pressure response (by identifying polymorphism that are beyond the classical thinking how renal denervation may exert blood pressure lowering effects).

Study design:

In collaboration with the Homburg Group (Prof. Dr. Felix Mahfoud), the investigators will extract DNA from stored samples of patients with uncontrolled treatment resistant hypertension and perform a genome wide association study analysis (GWAS) in two cohorts: no/low responders vs. high/excellent responders. NGS will be applied by the partners in Glasgow and Edinburgh. All patients with renal denervation will be categorized according to their pretreatment adjusted blood pressure response and the investigators will compare the upper quartile vs. the lower quartile of all patients that has been so far studied in Homburg and Erlangen. By excluding those patients with a medium or average blood pressure response, the investigators will have two distinct response patterns: low/no response vs. high/excellent response.

By applying standard biostatistics analysis, the investigators will come up with a pattern of polymorphism that are significantly different between the two groups. These identified polymorphisms (or a pattern of it) may be refer, not unexpectedly, to renin angiotensin aldosterone system, sodium and water balance, sympathetic nervous system or other endocrine parameters related to hypertension. In addition to that, the investigators may find significant results of polymorphisms involved in other pathophysiologic pathways not related to hypertension (by our current knowledge) and that the Investigators have not thought about to be related to uncontrolled hypertension. These novel mechanism need to be subsequently further analyzed, but they will offer the opportunity to find novel predictors of blood pressure response.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 300
• Est. completion date: December 31, 2023
• Est. primary completion date: July 23, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Individual is = 18 and = 85 years of age.

• Individual agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study

• Renal denervation = 6 months

• 24-h ABPM

Exclusion Criteria:

• Individual has renal artery anatomy that is ineligible for treatment including:

1. Main renal arteries < 4 mm in diameter or < 20 mm in length.

2. Hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which, in the eyes of the operator, would interfere with safe cannulation of the renal

3. A history of prior renal artery intervention including balloon angioplasty or stenting.

4. Multiple main renal arteries in either kidney.

• Individual has an estimated glomerular filtration rate (eGFR) of < 45mL/min/1.73m2, using the MDRD calculation.

• Individual has type 1 diabetes mellitus.

• Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of the screening visit, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques.

• Individual has a scheduled or planned surgery or cardiovascular intervention in the next 6 months.

• Individual has hemodynamically significant valvular heart disease for which reduction of blood pressure would be considered hazardous.

• Individual has an implantable cardioverter defibrillator (ICD) or pacemaker, or any other metallic implant which is not compatible with magnetic resonance imaging (MRI).

• Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, or significant anemia, or arrhythmias such as atrial fibrillation).

• Individual is pregnant, nursing or planning to be pregnant. [Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (hCG) pregnancy test prior to treatment.]

• Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.

• Individual is currently enrolled in another investigational drug or device trial

Related Conditions & MeSH terms

• Genetic Predisposition
• Genetic Predisposition to Disease
• Hypertension
• Renal Denervation

Intervention

Genetic:
• Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation
We attempt to idendtify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch.

Locations

Country	Name	City	State
Germany	Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg	Erlangen
Germany	Klinik für Innere Medizin III, Kardiologie, Angiologie Und Internistische Intensivmedizin, Saarland University Hospital, Saarland University	Homburg	Saarland
United Kingdom	Institute of Cardiovascular and Medical Science	Glasgow	Scotland

Sponsors (1)

Lead Sponsor	Collaborator
University of Erlangen-Nürnberg Medical School

Countries where clinical trial is conducted

Germany,  United Kingdom, 

References & Publications (11)

Delles C, Erdmann J, Jacobi J, Hilgers KF, Fleck E, Regitz-Zagrosek V, Schmieder RE. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension. J Am Coll Cardiol. 2001 Mar 1;37(3):878-84. doi: 10.1016/s0735-1097(00)01174-8. — View Citation

Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE. CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41. doi: 10.1097/01.fpc.0000175599.49764.98. — View Citation

Hilgers KF, Delles C, Veelken R, Schmieder RE. Angiotensinogen gene core promoter variants and non-modulating hypertension. Hypertension. 2001 Dec 1;38(6):1250-4. doi: 10.1161/hy1201.096545. — View Citation

Messerli FH, Bangalore S, Schmieder RE. Wilder's principle: pre-treatment value determines post-treatment response. Eur Heart J. 2015 Mar 1;36(9):576-9. doi: 10.1093/eurheartj/ehu467. Epub 2014 Dec 23. No abstract available. — View Citation

Ott C, Schneider MP, Delles C, Schlaich MP, Hilgers KF, Schmieder RE. Association of (pro)renin receptor gene polymorphism with blood pressure in Caucasian men. Pharmacogenet Genomics. 2011 Jun;21(6):347-9. doi: 10.1097/FPC.0b013e328344cdd2. — View Citation

Ott C, Schwarz T, Hilgers KF, Kreutz R, Schlaich MP, Schmieder RE. Left-ventricular structure and function are influenced by angiotensinogen gene polymorphism (-20 A/C) in young male patients. Am J Hypertens. 2007 Sep;20(9):974-80. doi: 10.1016/j.amjhyper.2007.03.008. — View Citation

Ott C, Titze SI, Schwarz TK, Kreutz R, Hilgers KF, Schmidt BM, Schlaich MP, Schmieder RE. High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. J Hypertens. 2007 Aug;25(8):1627-32. doi: 10.1097/HJH.0b013e3281cd40f5. — View Citation

Ritt M, Ott C, Delles C, Schneider MP, Schmieder RE. Impact of the endothelial nitric oxide synthase gene G894T polymorphism on renal endothelial function in patients with type 2 diabetes. Pharmacogenet Genomics. 2008 Aug;18(8):699-707. doi: 10.1097/FPC.0b013e32830500b1. — View Citation

Schmieder RE, Erdmann J, Delles C, Jacobi J, Fleck E, Hilgers K, Regitz-Zagrosek V. Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol. 2001 Jan;37(1):175-82. doi: 10.1016/s0735-1097(00)01063-9. — View Citation

Zolk O, Jacobi J, Pahl A, Fromm MF, Schmieder RE. MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007 Feb;17(2):137-44. doi: 10.1097/01.fpc.0000239969.46594.d0. — View Citation

Zolk O, Ott C, Fromm MF, Schmieder RE. Effect of the rs168924 single-nucleotide polymorphism in the SLC6A2 catecholamine transporter gene on blood pressure in Caucasians. J Clin Hypertens (Greenwich). 2012 May;14(5):293-8. doi: 10.1111/j.1751-7176.2012.00618.x. Epub 2012 Apr 9. — View Citation

* Note: There are 11 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identifying predictors of systolic blood pressure by 24-h ABPM	To identify predictors of systolic blood pressure response after renal denervation as evaluated by 24-h ABPM by using a GWA (genome wide association) approach.	6 months
Secondary	Identifying predictors of diastolic blood pressure by 24-h ABPM	To identify predictors of diastolic blood pressure response after renal denervation as evaluated by 24-h ABPM by using a GWA (genome wide association) approach.	6 months
Secondary	Identifying predictors of pulse pressure by 24-h ABPM	To identify predictors of pulse pressure response after renal denervation as evaluated by 24-h ABPM by using a GWA (genome wide association) approach.	6 months
Secondary	Identifying predictors of systolic blood pressure by office blood pressure	To identify predictors of systolic blood pressure response after renal denervation as evaluated by office blood pressure by using a GWA (genome wide association) approach.	6 months
Secondary	Identifying predictors of diastolic blood pressure by office blood pressure	To identify predictors of diastolic blood pressure response after renal denervation as evaluated by office blood pressure by using a GWA (genome wide association) approach.	6 months
Secondary	Identifying predictors of pulse pressure by office blood pressure	To identify predictors of pulse pressure response after renal denervation as evaluated by office blood pressure by using a GWA (genome wide association) approach.	6 months